Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM ET to discuss first-quarter 2022 financial results and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ending March 31, 2022. The previous release incorrectly stated the date as March 10. Jaguar Health focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal distress in humans and animals. For more details, register here.
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM Eastern Time to discuss first-quarter 2022 financial results and corporate updates. The earnings report will be filed on May 10, 2022, on Form 10-Q. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues in both humans and animals. The company is known for its drug candidate, crofelemer, which is currently involved in a pivotal Phase 3 clinical trial for diarrhea in cancer patients receiving targeted therapy.
Jaguar Health (NASDAQ:JAGX) has filed the final regulatory section with the FDA for conditional approval of its oral plant-based drug Canalevia to treat exercise-induced diarrhea (EID) in dogs. Canalevia would be the first treatment for EID in dogs to gain any form of FDA approval. Following conditional approval for chemotherapy-induced diarrhea (CID) in December 2021, Jaguar expects EID approval by Q4 2022. The FDA has confirmed the completeness of three of the four required technical sections for this application.
Jaguar Health (NASDAQ:JAGX) announced the commercial availability of Canalevia-CA1, the first FDA-approved treatment for chemotherapy-induced diarrhea (CID) in dogs. Following its conditional approval on December 21, 2021, this oral medication is now accessible through leading veterinary distributors in the U.S. The company highlights the unmet need for such a treatment, as over half of surveyed veterinarians noted CID disrupts cancer treatment in dogs. Canalevia-CA1, using the plant-based active ingredient crofelemer, aims to enhance dogs' comfort during chemotherapy.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that its CEO, Lisa Conte, will present at NobleCon18 on April 21, 2022, at 11:00 AM Eastern at the Hard Rock Hotel & Casino in Hollywood, Florida. Attendees can meet management during a breakout session at 10:00 AM. Registration for this investor conference is free via the provided link. A video of the presentation will be available the next day on Noble Capital Markets' website and archived for 90 days. Jaguar focuses on sustainable, plant-based medicines for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) has announced the replenishment of its New Employee Inducement Award Plan with 471,833 shares of common stock, effective June 16, 2020. This addition is on top of 500,000 shares registered previously on May 28, 2021. The plan aims to grant equity awards to new hires or former employees, serving as an inducement for their employment as per Nasdaq Listing Rule 5635(c)(4).
Jaguar focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) announces a dinner event for U.S. veterinary oncologists on April 12, 2022, in Puerto Vallarta, Mexico, coinciding with the Veterinary Cancer Society (VCS) Mid-Year Conference. The dinner will focus on chemotherapy-induced diarrhea (CID) treatment in dogs, featuring a private chef and entertainment. Canalevia-CA1 (crofelemer), the first FDA conditionally approved treatment for CID in dogs, will be showcased at the conference. The VCS Mid-Year Conference runs from April 9-12, 2022, at the Marriott Puerto Vallarta Resort & Spa.
Jaguar Health, Inc. has appointed Pravin Chaturvedi, PhD, as Chief Scientific Officer and Chair of the Scientific Advisory Board. Dr. Chaturvedi, with over 30 years in the pharmaceutical industry, will lead two key crofelemer pipeline development activities over the next 12-15 months. These include the Phase 3 OnTarget trial for cancer therapy-related diarrhea and collaborations for rare diseases like short bowel syndrome. Both initiatives aim to expand patient access and enhance Jaguar's market position, with completion expected soon.
Jaguar Health has entered a strategic agreement with Quadri Pharmaceuticals Store granting exclusive promotional, commercialization, and distribution rights for crofelemer in multiple Middle Eastern countries, including Saudi Arabia and the UAE. This agreement covers human indications approved in the U.S., specifically targeting HIV-related and cancer therapy-related diarrhea. The partnership aims to enhance access to crofelemer, which is currently undergoing a pivotal Phase 3 clinical trial. This initiative is crucial due to the rising HIV statistics in the region, highlighting the growing demand for effective treatments.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a recorded investor webcast on March 14, 2022, sharing company updates and 2021 financial results. Key initiatives include the ongoing OnTarget Phase 3 clinical trial for crofelemer, focused on preventing cancer therapy-related diarrhea. The company reported Mytesi net revenue of approximately $2.1 million in Q4 2021, a significant increase of 230% from Q3 2021. Additionally, Jaguar received FDA conditional approval in December 2021 for Canalevia™-CA1 treating chemotherapy-induced diarrhea in dogs.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
